STOCK TITAN

Royalty Pharma plc (RPRX) Stock News, Mar-Aug 2023

RPRX NASDAQ

Royalty Pharma plc reports developments tied to its biopharmaceutical royalty portfolio and life-sciences funding model. The company acquires existing royalties from medicine innovators and enters direct funding arrangements, including co-funding for late-stage clinical trials and product launches, in exchange for future royalties.

Recurring news covers Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, royalty transactions, and updates from commercial products and development-stage candidates. Company announcements also address R&D funding collaborations, portfolio clinical and regulatory developments, leadership additions in partnering and technology, investor conference appearances, and scientific initiatives such as the Royalty Pharma Translational Prize.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
dividends earnings
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
conferences
Rhea-AI Summary

The board of directors of Royalty Pharma (Nasdaq: RPRX) has declared a dividend of $0.20 per Class A ordinary share for the second quarter of 2023. This dividend will be distributed on June 15, 2023, to shareholders recorded by the close of business on May 19, 2023. Founded in 1996, Royalty Pharma is the largest purchaser of biopharmaceutical royalties, collaborating across the industry to fund innovation. Its portfolio includes royalties from over 35 commercial products like Vertex’s Trikafta and AbbVie’s Imbruvica, among others. The company plays a pivotal role in funding both late-stage clinical trials and acquiring existing royalties, supporting advancements in biopharmaceuticals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
dividends earnings
-
Rhea-AI Summary

Royalty Pharma (Nasdaq: RPRX) has announced its plan to report first quarter 2023 financial results on May 9, 2023, before the U.S. markets open. A conference call, available via webcast, will be held at 8:00 a.m. ET on the same day.

The company, established in 1996, is recognized as the largest buyer of biopharmaceutical royalties, funding innovation across the industry. Royalty Pharma collaborates with various organizations, including academic institutions and pharmaceutical companies, and currently holds a portfolio of royalties on over 35 commercial products, which includes notable therapies such as Vertex’s Trikafta and Biogen’s Tysabri.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
-
Rhea-AI Summary

Royalty Pharma plc (Nasdaq: RPRX) has authorized a share repurchase program of up to $1.0 billion for its Class A ordinary shares, with shareholder approval valid through June 2027. CEO Pablo Legorreta also plans to purchase an additional $50 million of these shares. This initiative reflects confidence in Royalty Pharma's growth potential and solid balance sheet, boosted by recent Biohaven-related payments. The company targets capital deployment of $10 to $12 billion over the next five years to invest in life sciences innovation while creating shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.53%
Tags
buybacks
Rhea-AI Summary

Royalty Pharma has acquired an interest in PureTech’s royalty from Karuna Therapeutics for its therapy, KarXT, valued at up to $500 million. This includes $100 million upfront and potentially $400 million based on milestones. PureTech maintains its 3.1% equity stake in Karuna and will receive milestone payments and a share of sublicense revenues. The acquisition offers non-dilutive funding for PureTech’s pipeline, which includes five clinical-stage candidates expected by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
none

FAQ

What is the current stock price of Royalty Pharma (RPRX)?

Royalty Pharma (RPRX) last closed at $68.45.

What is the market cap of Royalty Pharma (RPRX)?

The market cap of Royalty Pharma (RPRX) is approximately $39.3B.